What Melanoma Survival Numbers Do and Don't Tell You

Melanoma survival by stage, in plain numbers

Survival tracks closely with how far melanoma has spread at diagnosis. National SEER statistics group cases into three summary stages — localized (still in the skin), regional (spread to nearby lymph nodes), and distant (spread to far-off organs) — and report five-year relative survival for each 1Ref 1National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program (2025).Cancer Stat Facts: Melanoma of the Skin.US five-year relative survival for melanoma by SEER summary stage — about 99% localized, about 75% regional, about 35% distant, and about 94% for all stages combined — with roughly 8 in 10 diagnosed while localized.:

About 8 in 10 melanomas are found while still localized, which is why the combined figure sits so high 1Ref 1National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program (2025).Cancer Stat Facts: Melanoma of the Skin.US five-year relative survival for melanoma by SEER summary stage — about 99% localized, about 75% regional, about 35% distant, and about 94% for all stages combined — with roughly 8 in 10 diagnosed while localized.. These numbers are refreshed periodically, so the current values on the SEER page are the ones to trust. Five-year relative survival is about 99% for localized melanoma and about 35% once it has reached distant sites 1Ref 1National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program (2025).Cancer Stat Facts: Melanoma of the Skin.US five-year relative survival for melanoma by SEER summary stage — about 99% localized, about 75% regional, about 35% distant, and about 94% for all stages combined — with roughly 8 in 10 diagnosed while localized..

What 'relative survival' actually means

'Relative survival' is not the same as your personal chance of being alive in five years. It compares people with melanoma to similar people in the general population, which strips out deaths from unrelated causes — so it is a statement about the cancer's effect, not a literal countdown. Researchers who study how patients and doctors read these numbers have shown that survival rates are one of the easier figures to misunderstand, and that natural frequencies — 'about 75 out of 100 people' rather than percentages and ratios — are clearer and less misleading 2Ref 2Gigerenzer G, Gaissmaier W, Kurz-Milcke E, Schwartz LM, Woloshin S (2007).Helping Doctors and Patients Make Sense of Health Statistics.Survival rates are easily misunderstood, and natural frequencies communicate risk more clearly than percentages and ratios; relative-survival framing does not equate to an individual's chance of survival.. A five-year window is also a convention, not a finish line; many people live far longer, and the figure says nothing about year six. Relative survival compares a cancer group to the general population, isolating the disease's effect rather than predicting one person's outcome 2Ref 2Gigerenzer G, Gaissmaier W, Kurz-Milcke E, Schwartz LM, Woloshin S (2007).Helping Doctors and Patients Make Sense of Health Statistics.Survival rates are easily misunderstood, and natural frequencies communicate risk more clearly than percentages and ratios; relative-survival framing does not equate to an individual's chance of survival..

Two staging systems, two different meanings

The stage on a SEER chart and the stage a dermatologist or oncologist gives you are not the same scale. SEER uses three broad summary categories; the clinical system used to plan treatment is the American Joint Committee on Cancer (AJCC) staging, which runs from stage 0 through stage IV and is built from the tumor's thickness, whether its surface is ulcerated, and whether cancer has reached lymph nodes or beyond 3Ref 3Gershenwald JE, Scolyer RA, Hess KR, et al. (2017).Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.AJCC staging (0–IV) is built from tumor thickness (Breslow), ulceration, and nodal spread; the eighth edition revised thickness and nodal cutoffs and stage groupings.. The eighth edition refined those thickness and nodal cutoffs, which is one reason survival figures from different eras are not perfectly comparable 3Ref 3Gershenwald JE, Scolyer RA, Hess KR, et al. (2017).Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.AJCC staging (0–IV) is built from tumor thickness (Breslow), ulceration, and nodal spread; the eighth edition revised thickness and nodal cutoffs and stage groupings.. The National Cancer Institute's treatment summaries describe how these features drive both prognosis and the choice of surgery, sentinel lymph node biopsy, and drug therapy 4Ref 4National Cancer Institute (PDQ Adult Treatment Editorial Board) (2025).Melanoma Treatment (PDQ®)–Health Professional Version.Stage and tumor features drive prognosis and the choice among surgical excision, sentinel lymph node biopsy, immunotherapy, and targeted therapy; melanoma in situ is treated with excision.. When you look up a survival number, it helps to know which staging language it is written in and what the melanoma stages actually measure.

Why a survival number can't predict your outcome

A stage-based survival figure describes a large group of people diagnosed years ago — it cannot read your particular tumor, your overall health, or the treatments available now. Melanoma care has changed substantially: immunotherapy and targeted therapy have improved outcomes for advanced disease well beyond what older five-year windows captured, so today's numbers likely understate current results for later stages 4Ref 4National Cancer Institute (PDQ Adult Treatment Editorial Board) (2025).Melanoma Treatment (PDQ®)–Health Professional Version.Stage and tumor features drive prognosis and the choice among surgical excision, sentinel lymph node biopsy, immunotherapy, and targeted therapy; melanoma in situ is treated with excision.. Two people at the same stage can also have very different tumors underneath the label. This is why oncologists treat these statistics as context, not prediction. They are useful for understanding the shape of the disease and the value of early detection — and poor at forecasting any single person's path. Stage-based survival describes a past group, not your future; it is context, not a prediction.

Stage 0: melanoma in situ

The earliest stage, melanoma in situ, means the abnormal cells are still confined to the top layer of skin and have not invaded deeper — stage 0 in the AJCC system 3Ref 3Gershenwald JE, Scolyer RA, Hess KR, et al. (2017).Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.AJCC staging (0–IV) is built from tumor thickness (Breslow), ulceration, and nodal spread; the eighth edition revised thickness and nodal cutoffs and stage groupings.. Because it has not reached the blood vessels or lymphatics that let cancer travel, its outlook is excellent, and treatment is usually a surgical excision that removes the lesion with a margin of normal skin 4Ref 4National Cancer Institute (PDQ Adult Treatment Editorial Board) (2025).Melanoma Treatment (PDQ®)–Health Professional Version.Stage and tumor features drive prognosis and the choice among surgical excision, sentinel lymph node biopsy, immunotherapy, and targeted therapy; melanoma in situ is treated with excision.. In situ disease is a large part of why melanoma's overall survival figures look so favorable: catching it here, before it becomes invasive, is the single biggest lever on outcome. It is also the strongest argument for paying attention to a new or changing spot early rather than waiting to see what it does.

How thickness and lymph nodes are measured

Two measurements do most of the work in staging invasive melanoma. The first is Breslow thickness — how deep the tumor extends, in millimeters, measured under the microscope from a full-thickness biopsy; thinner tumors carry a better prognosis than thicker ones 3Ref 3Gershenwald JE, Scolyer RA, Hess KR, et al. (2017).Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.AJCC staging (0–IV) is built from tumor thickness (Breslow), ulceration, and nodal spread; the eighth edition revised thickness and nodal cutoffs and stage groupings.. The second is whether melanoma has reached the nearby lymph nodes, often assessed with a sentinel lymph node biopsy. A large randomized trial found that immediately removing all the lymph nodes after a positive sentinel node improved regional disease control and gave prognostic information, but did not improve melanoma-specific survival compared with careful ultrasound monitoring 5Ref 5Faries MB, Thompson JF, Cochran AJ, et al. (2017).Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.Immediate completion lymph-node dissection after a positive sentinel node improved regional disease control and gave prognostic information but did not improve melanoma-specific survival versus nodal observation with ultrasound.. That is why node surgery is now a more individualized decision than it once was, and why the Breslow depth on your pathology report carries so much weight.

What to take from the numbers

The honest summary is that stage at diagnosis is the biggest thing survival statistics reveal, and that they are far better at showing why early detection matters than at telling any one person what will happen. If you are reading these figures because of a recent diagnosis, the numbers your own care team gives you — based on your specific tumor and its stage — will always be more meaningful than a population average. And if you are reading them out of worry about a spot, the takeaway is simpler still: the earlier a melanoma is found, the better the odds sit, which is the whole case for getting a changing mole checked rather than waiting.